

AMENDMENTS TO THE CLAIMS

1. (Withdrawn) A process for the preparation of a pharmaceutical composition comprising an active pharmaceutical ingredient capable of existing in multiple polymorphic forms, comprising a step of preparation of a wet phase comprising said active pharmaceutical ingredient and microcrystalline cellulose and a liquid, wherein in said wet phase has a weight ratio of active pharmaceutical ingredient to microcrystalline cellulose above 1.0 or a weight ratio of active pharmaceutical ingredient to liquid above 1.0.
2. (Withdrawn) A process according to claim 1 wherein said wet phase is an alcoholic phase and in said wet phase the weight ratio of active pharmaceutical ingredient to microcrystalline cellulose is above 1.0 and the weight ratio of active pharmaceutical ingredient to alcoholic liquid is above 1.0.
3. (Withdrawn) A process according to claim 1 wherein said weight ratio of active pharmaceutical ingredient to the liquid is above 2.0.
4. (Withdrawn) A process according to claim 1 wherein said liquid is an alcoholic liquid consisting of only absolute ethanol or of an aqueous ethanol solution.
5. (Withdrawn) A process according to claim 1 wherein said microcrystalline cellulose is incorporated into the composition in more than one step.
6. (Withdrawn) A process according to claim 1 wherein the active pharmaceutical

ingredient is pravastatin sodium.

7. (Withdrawn) A process according to claim 6 wherein the liquid is ethanol and the weight ratio of pravastatin sodium to microcrystalline cellulose is above 1.0 and the weight ratio of pravastatin sodium to ethanol is above 2.0.
8. (Withdrawn) A process according to claim 1 wherein the active pharmaceutical ingredient is crystalline pravastatin sodium having characteristic peaks in a X-ray diffractogram at 2θ of 4, 10.2, 16.3, 17.3, and 20.0 ± 0.2°.
9. (Withdrawn) A process according to claim 8 wherein the crystalline pravastatin sodium exhibits an X-ray diffraction pattern substantially similar to that in Figure 2 of US 6,740,775.
10. (Withdrawn) A process according to claim 6 whereby pravastatin sodium in a first polymorph form is stabilized against conversion into a polymorph form which exhibits broad peaks in X-ray diffraction pattern, having half-value widths of significant peaks above 2° 2 Theta.
11. (Withdrawn) A process according to claim 1 wherein a binder is incorporated into the composition in a step other than the step of preparation of an alcoholic phase.
12. (Withdrawn) A process according to claim 11 wherein said binder is polyvinylpyrrolidone (PVP).
13. (Canceled).

14. (Currently Amended) A stabilized pharmaceutical composition comprising a polymorph form of pravastatin sodium and microcrystalline cellulose in a ratio of pravastatin sodium to microcrystalline cellulose greater than one, wherein the greater than one ratio of pravastatin sodium to microcrystalline cellulose occurs at least in a wet phase, wherein the polymorph of pravastatin sodium exhibits an X-Ray diffraction pattern with peaks having half-value widths below $2^{\circ} 2 \text{ Theta}$ and is stabilized against converting into one exhibiting peaks in an X-ray diffraction pattern having half-value widths of peaks above $2^{\circ} 2 \text{ Theta}$, and wherein a sample of said composition subjected to accelerated stability testing at 60 degrees centigrade remains stable after one month after being prepared.
15. (Withdrawn) A method of using the pharmaceutical composition according to claim 13 for the manufacture of a medicament for the treatment of hypercholesterolemia.
16. (Withdrawn) A method of preventing or treating hypercholesterolemia in a susceptible patient, comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 13.
17. (Canceled).
18. (Previously presented) The pharmaceutical composition of claim 14, wherein the wet phase comprises alcohol and the ratio of pravastatin sodium to alcohol is greater than one.

19. (Previously presented) The pharmaceutical composition of claim 18, which has been dried and formulated into a capsule or tablet.
20. (Canceled).
21. (Currently Amended) The pharmaceutical composition of ~~either claim 13 or 14~~, wherein in at least a wet phase, the ratio of pravastatin sodium to microcrystalline cellulose is at least 2.